
The AZURE-4 study met its goal of reducing hepatitis delta virus levels as Mirum prepares for a potential FDA marketing application.
Mirum Pharmaceuticals said its experimental treatment brelovitug met the goal of lowering virus levels in the AZURE-4 Phase 3 study of chronic hepatitis delta.
The company is also studying brelovitug in AZURE-1, which showed similar antiviral activity, according to the source. The treatment is a monoclonal antibody.
Mirum is preparing to apply to the U.S. Food and Drug Administration for marketing approval, the report said. The application has not yet been described as filed.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.